News round-up for 8-12 July by DDW Senior Digital Content Editor Diana Spencer.

Clinical trial news has caught our attention this week. Despite the revelation from Phesi that a third of clinical trials fail at Phase II, DDW has reported positive human trial updates on therapeutics for myasthenia gravis, non-small cell lung cancer, Marburg virus, and Parkinson’s disease.

The top stories:

Antibody fragment shows promise in myasthenia gravis

argenx shared trial and real-world data on Vyvgart (efgartigimod alfa) in patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

Mission awarded $5.2m for disease-modifying Parkinson’s treatment

Mission Therapeutics has been awarded $5.2 million from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Parkinson’s UK.

Cancer ‘master switch’ study expands to lung cancer

iOnctura has expanded its clinical trial programme for roginolisib to include non-small cell lung cancer (NSCLC).

First-in-human vaccine trial for deadly Marburg virus

Scientists at the University of Oxford in the UK have launched a new clinical trial to test a vaccine to protect against “devastating” Marburg virus.

Increase in diabetes research fuelled by GLP-1s like Ozempic

Covid-19 is no longer in the top five most studied indications, replaced by type 2 diabetes, according to Phesi’s mid-year analysis of clinical trials.